A U.S. federal district court in Delaware ordered Guardant Health Inc. to pay more than $245.2 million in damages and royalties for infringing patents related to TwinStrand Biosciences' Duplex Sequencing technology.
The judgment, issued on August 21, 2026, includes an initial award of $83.4 million for infringement up to June 30, 2023, supplemented by $19.5 million for sales between July 1, 2023, and February 5, 2024. Accumulated royalties of $119.4 million cover sales from February 5, 2024, to May 31, 2026, with an additional $22.9 million in interest.
Starting June 1, 2026, Guardant Health must pay a 6% ongoing royalty on sales of 11 covered products and services, including Guardant360 Lab Developed Test and GuardantOMNI, until the patents expire on March 15, 2033. The jury applied the 6% rate to revenues representing approximately 90% of Guardant Health's total revenue during the infringement period.
The court upheld the validity of patents US 10.287.631 and US 10.760.127, denying Guardant Health's post-trial motions to overturn the verdict or grant a new trial. All of Guardant Health's counterclaims against TwinStrand were dismissed or withdrawn prior to trial.
Guardant Health is required to provide TwinStrand and the University of Washington with quarterly accounting of U.S. sales for the covered products and services.
